Empagliflozin
Empagliflozin is a selective inhibitor of sodium-glucose cotransporter-2 (SGLT2), the transporter that reabsorbs most filtered glucose in the proximal tubule.
Empagliflozin is a selective inhibitor of sodium-glucose cotransporter-2 (SGLT2), the transporter that reabsorbs most filtered glucose in the proximal tubule. Blocking it lowers the renal threshold for glucose, so glucose is excreted in the urine and blood levels fall without any action on insulin secretion — which is why the drug does not cause hypoglycemia by itself and works regardless of remaining β-cell function. glucose lost in the urine carries water and sodium with it, producing a mild osmotic diuresis and natriuresis, and the restored sodium delivery to the macula densa reactivates tubuloglomerular feedback, constricting the afferent arteriole and lowering intraglomerular pressure. That last effect explains the characteristic early dip in estimated glomerular filtration rate that precedes long-term renal preservation, and is the leading account of why the class protects kidneys.
Originally approved for type 2 diabetes, empagliflozin's indications now extend to heart failure with reduced or preserved ejection fraction and to chronic kidney disease, in both cases with benefit in patients who do not have diabetes at all — evidence that the cardiorenal effect is not a consequence of glucose lowering. Proposed mechanisms include reduced preload and afterload, a shift in myocardial fuel use toward ketone bodies, reduced cardiac fibrosis and inflammation, and effects on sodium-hydrogen exchange. Its action is complementary to agents working through other pathways, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, which enhance glucose-dependent insulin secretion, and metformin, which chiefly suppresses hepatic glucose production and improves insulin sensitivity, making it a frequent combination partner.
The predictable adverse effects follow from the mechanism: glucose in the urine promotes genital mycotic infection, the diuresis can cause volume depletion and hypotension in patients already on diuretics, and shifting metabolism toward fat oxidation while glucose is excreted can precipitate ketoacidosis at near-normal blood glucose, which is easy to miss and warrants perioperative interruption. Beyond glycemic control, reported pleiotropic actions across cardiovascular, renal and gut tissue — modulation of AMPK/mTOR signaling, reduced proinflammatory cytokines, attenuated oxidative stress — are pursued as explanations for benefits that exceed what SGLT2 inhibition alone would predict, though the boundary between class effect and off-target action remains unsettled.
Where the papers sit
14 papers from the last 6 months study empagliflozin directly · updated from PubMed 12 Oct 2026
Study type 3 clinical trials · 1 observational · 1 human data · 6 preclinical · 3 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Type 2 Diabetes Therapy
Metformin–empagliflozin combinations are being evaluated for glycaemic efficacy and safety in type 2 diabetes. Add-on anagliptin and comparisons with dapagliflozin or DPP-4 inhibitors extend the focus to treatment selection and real-world outcomes. Semaglutide and empagliflozin are also being assessed for effects on endothelial function. Analytical assays and a preclinical Parkinsonism study broaden the evidence beyond routine diabetes care.
7 papers · 50%
-
Myocardial Ischemia-Reperfusion Injury
Myocardial ischemia-reperfusion injury is being linked to metabolic failure, oxidative stress, and inflammatory cell-death pathways. Empagliflozin improves myocardial metabolism and coronary function in diabetic and non-diabetic injury models. Mitochondrial oxidative damage and PANoptosis emerge as mechanisms by which advanced glycation end-products worsen injury. The work points toward antioxidant and metabolic protection, but the evidence remains preclinical.
2 papers · 14.3%
-
Others — Cardiovascular and Organ Effects
Post-discharge heart-failure care is the clearest clinical focus, with early empagliflozin initiation assessed against delayed or absent treatment for mortality and hospitalisation. Comparative work contrasts empagliflozin with dapagliflozin for major adverse cardiovascular events. Separate studies examine nose-to-brain delivery in Alzheimer’s disease, colonic barrier repair in glycogen storage disease type Ib, and brain-derived neurotrophic factor after hyponatremia correction. The cluster therefore has no single biological or clinical subject.
5 papers · 35.7%
Empagliflozin can protect diseased tissues through direct local mechanisms rather than only through its established metabolic effects
In streptozotocin-diabetic and non-diabetic rat hearts subjected to ischemia/reperfusion, empagliflozin improved myocardial and coronary function while altering myocardial metabolism, inflammation, oxidative stress, and angiocrine signaling 41995817Apr; in glycogen storage disease type Ib patients, mice, intestinal organoids, and epithelial cells, it directly restored the colonic mucus barrier through an AMPK/SOX4 pathway, promoting mucin production and goblet-cell preservation 42133539May. Together, these findings replace a framework centered on systemic glucose-lowering with one in which empagliflozin can exert tissue-specific protective and reparative actions, including in non-diabetic hearts and intestinal epithelium.
Empagliflozin is developed as a nose-to-brain treatment for Alzheimer disease
In a sporadic Alzheimer disease rat model, empagliflozin-loaded nanostructured lipid carriers incorporated into an intranasal in situ gel improved nasal retention, brain-directed delivery, pharmacokinetic exposure, and cognitive memory 42323146Jun. This assigns empagliflozin a role not represented by the other papers: an intranasal, brain-targeted therapeutic platform for Alzheimer disease rather than a systemic metabolic, cardiovascular, intestinal, analytical, or combination-treatment agent.
Papers
The 14 papers from the last 6 months that study empagliflozin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Type 2 Diabetes Therapy (7)
- Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China. Journal of diabetes · 28 Sept 2026 PMID 42802896
- Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. Scientific reports · 9 Sept 2026 PMID 42711364
- Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial. Journal of diabetes and its complications · 1 Sept 2026 PMID 42679726
- Development and validation of a stability-indicating LC-MS/MS method for simultaneous estimation of empagliflozin and metoprolol in pharmaceutical dosage forms with forced degradation studies and computational assessment of degradation products. The Analyst · 29 Jul 2026 PMID 42523027
- Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study. Scientific reports · 24 Jun 2026 PMID 42342812
- Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples. Scientific reports · 20 May 2026 PMID 42162103
- Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. Diabetes research and clinical practice · 26 Apr 2026 PMID 42036072
Myocardial Ischemia-Reperfusion Injury (2)
- Advanced glycation end-products exacerbate myocardial ischemia/reperfusion injury by promoting mitochondrial oxidative damage and PANoptosis in diabetes mellitus. Redox biology · 23 May 2026 PMID 42176503
- Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion. Basic research in cardiology · 17 Apr 2026 PMID 41995817
Others — Cardiovascular and Organ Effects (5)
- Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation. ESC heart failure · 22 Sept 2026 PMID 42770322
- Hyponatremia correction is associated with increased brain-derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double-blind, placebo-controlled, crossover trial. Journal of neuroendocrinology · 29 Jul 2026 PMID 42522233
- Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study. British journal of clinical pharmacology · 26 Jun 2026 PMID 42357835
- Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer's disease. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 20 Jun 2026 PMID 42323146
- Empagliflozin Restores the Colonic Mucous Barrier by an AMPK/SOX4-Dependent Pathway in Glycogen Storage Disease Type Ib. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 14 May 2026 PMID 42133539
By study type
Clinical trials (3)
- Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial. Journal of diabetes and its complications · 1 Sept 2026 PMID 42679726
- Hyponatremia correction is associated with increased brain-derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double-blind, placebo-controlled, crossover trial. Journal of neuroendocrinology · 29 Jul 2026 PMID 42522233
- Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. Diabetes research and clinical practice · 26 Apr 2026 PMID 42036072
Observational studies and case reports (1)
- Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China. Journal of diabetes · 28 Sept 2026 PMID 42802896
Human data, design not indexed (1)
- Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples. Scientific reports · 20 May 2026 PMID 42162103
Preclinical: animal, cell and lab studies (6)
- Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. Scientific reports · 9 Sept 2026 PMID 42711364
- Development and validation of a stability-indicating LC-MS/MS method for simultaneous estimation of empagliflozin and metoprolol in pharmaceutical dosage forms with forced degradation studies and computational assessment of degradation products. The Analyst · 29 Jul 2026 PMID 42523027
- Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer's disease. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 20 Jun 2026 PMID 42323146
- Advanced glycation end-products exacerbate myocardial ischemia/reperfusion injury by promoting mitochondrial oxidative damage and PANoptosis in diabetes mellitus. Redox biology · 23 May 2026 PMID 42176503
- Empagliflozin Restores the Colonic Mucous Barrier by an AMPK/SOX4-Dependent Pathway in Glycogen Storage Disease Type Ib. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 14 May 2026 PMID 42133539
- Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion. Basic research in cardiology · 17 Apr 2026 PMID 41995817
Unclassified: not yet indexed with MeSH (3)
- Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation. ESC heart failure · 22 Sept 2026 PMID 42770322
- Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study. British journal of clinical pharmacology · 26 Jun 2026 PMID 42357835
- Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study. Scientific reports · 24 Jun 2026 PMID 42342812
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-09-24 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.